Dr. Christoph Uherek
Head of Preclinical Development
Biotest AG: BT-062 - A Potent Antibody-Drug Conjugate for the Treatment of CD138 Expressing Tumors
BT-062 is an antibody-drug conjugate binding to CD138, which is over-expressed on multiple myeloma (MM) and a variety of solid tumors. BT-062 has shown good tolerability in clinical phase I/II studies and achieved clinical benefit in MM patients. Additionally, BT-062 demonstrated very good efficacy in solid tumor animal models (e.g. triple negative breast cancer), making it a promising candidate for development in solid tumor indications.